Improving the Lives of Patients with Cancer and Inflammatory Diseases Exploring the Biological Drivers in Inflammation Developing Novel Therapeutics that Halt Disease Progression

ABOUT ENZYCHEM LIFESCIENCES

Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.

PLATFORM TECHNOLOGY

EC-18 targets anti-inflammatory
pathway

Broad therapeutic platform

Developing first-in-class small molecules to target
fundamental inflammation pathways

EC-18 PIPELINE

DEVELOPMENT STAGE

CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis

Press Releases